Callio Therapeutics
Multi-payload antibody-drug conjugates
Seattle, United States · Founded 2025 · $187.0M raised
- Headquarters
- Seattle, Washington
- Employees
- 1–10
- Founded
- 2025
- Business Model
- B2B
- Website
- calliotx.com
- Total Funding
- $187.0M
- Last Round
- $187.0M Series AMar 2025
- Rounds
- 1
About
Callio Therapeutics is a clinical-stage biotechnology company developing next-generation multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. Founded in 2025 and headquartered in Seattle and Singapore, the company's lead program CLIO-8221 is a dual-payload ADC targeting HER2-expressing solid tumors that delivers a topoisomerase 1 inhibitor and an ATR inhibitor simultaneously to overcome resistance to existing ADC therapies.
Summary
Callio Therapeutics is a Biotech company based in Seattle, United States, founded in 2025. It has raised $187.0M in total across 1 round, most recently a $187.0M Series A round in Mar 2025.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2025
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...